Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
CHESTER, N.J., June 12, 2017 -- Hillstream BioPharma Inc. (Hillstream), a biopharmaceutical company focused on developing targeted, safer and more effective cancer therapeutics, will present at the 2017 Marcum MicroCap Conference on June 16 at the Grand Hyatt in New York City. Randy Milby, Chief Executive Officer, will present an update on the company and answer questions at 11:00 am ET.
Hillstream BioPharma Inc. is dedicated to developing cancer therapeutics with greater safety and efficacy to help patients with high unmet medical needs. Hillstream’s lead drug, HBP-407, is a novel proprietary formulation of bortezomib, with an improved side effect profile with the potential for reduced peripheral neuropathy, activity against bortezomib-resistant multiple myeloma and a highly targeted effect with the potential for an increased dose to expand the first approved proteasome inhibitor into solid tumors.
Randy Milby, Hillstream’s CEO, said, “Side effects, such as peripheral neuropathy, and drug resistance are two serious problems in cancer patient care. We believe HBP-407 can offer a safer, more effective targeted therapeutic in an orphan population with a high unmet need.”
The Marcum MicroCap Conference (www.marcummicrocap.com) is a nationally recognized forum for publicly traded companies with less than $500 million in market capitalization to network with fund managers and high net worth investors who focus on small cap equities. More than 2000 investors and other participants from every segment of the microcap marketplace attend each year, including venture and lower middle-market private equity investors, institutional investors, directors, investment bankers, and buy- and sell-side analysts, as well as senior executive teams from presenting companies and service providers to the microcap marketplace.
The conference is presented by Marcum LLP, a top national accounting and advisory firm registered with the Public Company Accounting Oversight Board (PCAOB). Marcum's Assurance Division provides the most up-to-date service and guidance on SEC accounting and reporting issues. For more information, visit www.marcumllp.com.
About Hillstream BioPharma Inc.
Hillstream BioPharma Inc. (Hillstream) is a biopharmaceutical company focused on developing cancer therapeutics with greater safety and efficacy to help patients with high unmet medical needs. Hillstream’s lead drug, HBP-407, is a novel proprietary formulation of bortezomib, with an improved side effect profile with the potential for reduced peripheral neuropathy, activity against bortezomib-resistant multiple myeloma and a highly targeted effect with the potential for increased dose to expand the first approved proteasome inhibitor into solid tumors. Hillstream will initially utilize the faster and more de-risked FDA’s 505(b)(2) NDA regulatory pathway for approval of HBP-407. Our goal is to develop pharmaceutical products which play an important role in helping patients lead longer and healthier lives. Please also see www.hillstreambio.com.
Contact: Randy Milby [email protected] www.hillstreambio.com
